[Federal Register Volume 67, Number 220 (Thursday, November 14, 2002)]
[Notices]
[Pages 69015-69016]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-28884]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 01E-0091]
Determination of Regulatory Review Period for Purposes of Patent
Extension; ACOVA
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for ACOVA and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Commissioner of
Patents and Trademarks, Department of Commerce, for the extension of a
patent which claims that human drug product.
ADDRESSES: Submit written comments and petitions to the Dockets
Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to
http://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Office of
Regulatory Policy (HFD-013), Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301-827-3460.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug
[[Page 69016]]
product, medical device, food additive, or color additive) was subject
to regulatory review by FDA before the item was marketed. Under these
acts, a product's regulatory review period forms the basis for
determining the amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Commissioner of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted, as well as any time that may have occurred before the
patent was issued), FDA's determination of the length of a regulatory
review period for a human drug product will include all of the testing
phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product ACOVA
(argatroban). ACOVA is an anticoagulant for prophylaxis or treatment of
thrombosis in patients with heparin-induced thrombocytopenia.
Subsequent to this approval, the Patent and Trademark Office received a
patent term restoration application for ACOVA (U.S. Patent No.
5,214,052) from Texas Biotechnology Corp., and the Patent and Trademark
Office requested FDA's assistance in determining this patent's
eligibility for patent term restoration. In a letter dated May 3, 2001,
FDA advised the Patent and Trademark Office that this human drug
product had undergone a regulatory review period and that the approval
of ACOVA represented the first permitted commercial marketing or use of
the product. Shortly thereafter, the Patent and Trademark Office
requested that FDA determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
ACOVA is 4,022 days. Of this time, 2,971 days occurred during the
testing phase of the regulatory review period, while 1,051 days
occurred during the approval phase. These periods of time were derived
from the following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective:
June 28, 1989. The applicant claims January 12, 1989, as the date the
investigational new drug application (IND) became effective. However,
FDA records indicate that the IND effective date was June 28, 1989,
which was 30 days after FDA receipt of the IND.
2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the act: August 15,
1997. The applicant claims August 20, 1997, as the date the new drug
application (NDA) for ACOVA (NDA 20-883) was initially submitted.
However, FDA records indicate that NDA 20-883 was submitted on August
15, 1997.
3. The date the application was approved: June 30, 2000. FDA has
verified the applicant's claim that NDA 20-883 was approved on June 30,
2000.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 839 days of
patent term extension.
Anyone with knowledge that any of the dates as published is
incorrect may submit to the Dockets Management Branch (see ADDRESSES)
written or electronic comments and ask for a redetermination by January
13, 2003. Furthermore, any interested person may petition FDA for a
determination regarding whether the applicant for extension acted with
due diligence during the regulatory review period by May 13, 2003. To
meet its burden, the petition must contain sufficient facts to merit an
FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp.
41-42, 1984.) Petitions should be in the format specified in 21 CFR
10.30.
Comments and petitions should be submitted to the Dockets
Management Branch. Three copies of any information is to be submitted,
except that individuals may submit one copy. Comments are to be
identified with the docket number found in brackets in the heading of
this document. Comments and petitions may be seen in the Dockets
Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
Dated: September 24, 2002.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. 02-28884 Filed 11-13-02; 8:45 am]
BILLING CODE 4160-01-S